LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

LLY

751.96

-3.18%↓

JNJ

155.56

-1.06%↓

UNH

385.73

-1.37%↓

ABBV

185.44

-1.29%↓

ABT

133.82

-0.01%↓

Search

Exelixis Inc

Closed

SectorHealthcare

36.52 -0.76

Overview

Share price change

24h

Current

Min

34.72

Max

37.04

Key metrics

By Trading Economics

Income

140M

Sales

27M

567M

P/E

Sector Avg

22.636

54.379

EPS

0.55

Profit margin

24.678

Employees

1,147

EBITDA

171M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+3.86% upside

Dividends

By Dow Jones

Next Earnings

13 May 2025

Market Stats

By TradingEconomics

Market Cap

1.5B

11B

Previous open

37.28

Previous close

36.52

News Sentiment

By Acuity

21%

79%

44 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Exelixis Inc Chart

Past performance is not a reliable indicator of future results.

Related News

8 May 2025, 23:59 UTC

Top News
Earnings

Naver 1Q Net Slumps on Higher Costs

8 May 2025, 23:39 UTC

Earnings

OCBC 1Q Net Down on Lower Interest Income

8 May 2025, 23:01 UTC

Earnings

Macquarie Raises Dividend After 5.5% Rise in Annual Profit -- Update

8 May 2025, 22:52 UTC

Earnings

REA Expects Annual Listings Growth Despite April Decline

8 May 2025, 22:46 UTC

Earnings

Macquarie Raises Dividend After 5.5% Rise in Annual Profit

8 May 2025, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

8 May 2025, 23:45 UTC

Market Talk

Nikkei May Rise as Tariffs Fears Ease -- Market Talk

8 May 2025, 23:41 UTC

Market Talk

Gold Rises on Possible Technical Recovery; Gains May be Capped by Risk-on Mood -- Market Talk

8 May 2025, 23:30 UTC

Earnings

Itau Unibanco 1Q Rev BRL45.02B >ITUB

8 May 2025, 23:29 UTC

Earnings

Itau Unibanco 1Q EPS BRL1.03 >ITUB

8 May 2025, 23:22 UTC

Earnings

Naver 1Q Net Profit Largely Met FactSet-Compiled Consensus

8 May 2025, 23:22 UTC

Earnings

Naver 1Q Net KRW423.70B Vs. Net KRW555.80B >035420.SE

8 May 2025, 23:21 UTC

Earnings

Naver 1Q Oper Pft KRW505.30B Vs. Pft KRW439.30B >035420.SE

8 May 2025, 23:21 UTC

Earnings

Naver 1Q Rev KRW2.787T Vs. KRW2.526T >035420.SE

8 May 2025, 23:17 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.35B Vs. S$2.44B >O39.SG

8 May 2025, 23:17 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Total Income S$3.66B Vs. S$3.63B >O39.SG

8 May 2025, 23:17 UTC

Earnings

Oversea-Chinese Banking Corp. 1Q Net S$1.88B Vs. Net S$1.98B >O39.SG

8 May 2025, 23:05 UTC

Market Talk

ANZ Could Cut Dividend by 10% From 2H -- Market Talk

8 May 2025, 23:05 UTC

Market Talk

Global Equities Roundup: Market Talk

8 May 2025, 23:01 UTC

Top News

With U.K. Deal, U.S. Signals That 10% Tariff on World Is New Baseline -- WSJ

8 May 2025, 22:28 UTC

Earnings

REA Expects FY 2025 Listings Growth of 1-2%

8 May 2025, 22:28 UTC

Earnings

REA Says April Listings Decline Reflects Year Ago Strength, Timing of Easter and Election

8 May 2025, 22:27 UTC

Earnings

REA Says April Sydney, Melbourne Listings Both Down 16% on Year

8 May 2025, 22:27 UTC

Earnings

REA Says April Residential Listings Fell by 11% on Year

8 May 2025, 22:26 UTC

Earnings

REA 3Q Operating Expenses A$176 Million, Up 12% on Year

8 May 2025, 22:26 UTC

Earnings

REA 3Q Free Cash Flow A$132 Million, Up 19% on Year

8 May 2025, 22:26 UTC

Earnings

REA 3Q Operating Ebitda A$199 Million, Up 12% on Year

8 May 2025, 22:26 UTC

Earnings

REA Nine-Months Free Cash Flow A$389 Million, Up 21% on Year

8 May 2025, 22:25 UTC

Earnings

REA Nine-Months Operating Expenses A$513 Million, Up 15% on Year

8 May 2025, 22:25 UTC

Earnings

REA Nine-Months Operating Ebitda A$734 Million, Up 19% on Year

Peer Comparison

Price change

Exelixis Inc Forecast

Price Target

By TipRanks

3.86% upside

12 Months Forecast

Average 38.23 USD  3.86%

High 45 USD

Low 29 USD

Based on 15 Wall Street analysts offering 12 month price targets forExelixis Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

15 ratings

10

Buy

5

Hold

0

Sell

Technical Score

By Trading Central

N/A / 36.6Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bearish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

44 / 382 Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Exelixis Inc

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement and collaboration with Sairopa B.V. and Merck & Co., Inc. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.